- Home
- RAPT vs ELVN Comparison
RAPT vs ELVN Comparison
Compare RAPT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAPT | ELVN |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | 60 | 65 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RAPT | ELVN |
|---|---|---|
| Price | $58.00 | $29.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $56.22 | $41.00 |
| AVG Volume (30 Days) | ★ 4.1M | 625.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.97 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $13.30 |
| 52 Week High | $57.99 | $30.22 |
Technical Indicators
Market Signals| Indicator | RAPT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 64.16 |
| Support Level | $32.00 | $18.41 |
| Resistance Level | N/A | $29.63 |
| Average True Range (ATR) | 0.09 | 1.36 |
| MACD | -0.79 | 0.05 |
| Stochastic Oscillator | 95.31 | 85.44 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.